Best CROs for Clinical Trials

As of February 2026, several Contract Research Organizations (CROs) have distinguished themselves in the clinical trials sector through their comprehensive services, global reach, and innovative approaches. Here are some of the top CROs:

Worldwide Clinical Trials
Recognized as a top performer in the 2024 Industry Standard Research (ISR) Phase II/III Benchmarking Report, Worldwide Clinical Trials excels in overall performance, delivery factors, and staff characteristics. (worldwide.com)

IQVIA
A global leader in healthcare data analytics, IQVIA offers extensive clinical trial services, including real-world evidence analytics and central lab services. In 2024, they launched an Observational Health Data Analytics suite tailored to cancer research. (quanticate.com)

ICON plc
With a global presence in over 50 countries, ICON provides a wide range of services, including adaptive trials and biosimilars. In 2024, ICON completed its integration of PRA Health Sciences, enhancing its late-phase capacity in Asia. (quanticate.com)

Parexel
Offering full-service clinical research from Phase I to IV, Parexel has over 21,000 collaborators worldwide. In 2023, Parexel was named "Best Contract Research Organization" at the Scrip Awards for innovation in patient engagement and diversity. (nature.foleon.com)

Medpace
A full-service CRO with over 30 years of experience, Medpace specializes in Phase I to IV clinical trials. In 2024, Medpace opened two new early-phase units in Europe, boosting first-in-human capacity by 30%. (quanticate.com)

When selecting a CRO, consider factors such as therapeutic expertise, geographic reach, regulatory compliance, and technological capabilities to ensure alignment with your clinical trial requirements.

Based on my search results, here are the best CROs (Contract Research Organizations) for clinical trials in 2025:

Top-Tier Global CROs by Revenue and Market Leadership

1. IQVIA

IQVIA is the world's largest CRO with $15.4 billion in revenue for 2024
.
IQVIA has the largest revenue base in the CRO market and an unrivalled analytics stack
.
IQVIA offers clients a unique combination of advanced data analytics, artificial intelligence (AI), and machine learning, known as their "Human Data Science" approach
.

2. Thermo Fisher Scientific (PPD Division)

Thermo Fisher Scientific (PPD Division) led the pack with $6 billion in revenue, highlighting its scale as one of the largest global clinical trial service organizations
.
The company emerged as a significant player through its $17.4 billion acquisition of PPD, Inc. in 2021
.

3. ICON

According to Clinical Trials Arena, ICON was the most used CRO for new study starts in 2024
.
ICON reported full-year 2024 revenue of $8.28 billion
and
operates out of 106 locations across 55 countries
.
In July 2024, ICON was recognized for its excellence in clinical research in all categories at the CRO Leadership Awards
.

4. Parexel

Founded over 40 years ago and providing the full range of Phase I to IV clinical development services, Parexel remains one of the biggest CROs in the world
.
With a team of more than 21,000 professionals worldwide, the company has a wide range of service offerings
.

5. Labcorp (formerly Covance)

Labcorp, formerly known as Covance, is a prominent name in clinical research offering services in early-stage clinical research, clinical pharmacology, and regulatory consulting
.
Labcorp combines one of the world's largest central lab networks with full clinical trial services
.

Mid-Sized High-Performing CROs

6. Syneos Health

Syneos is a widely recognized global CRO with operations in over 110 countries worldwide
.
In June 2024, Syneos Health was recognized on the Forbes list of America's Best Management Consulting Firms 2024
.

7. Medpace

Medpace delivered standout growth with $603 million in revenue and a 14.2% YoY increase
.
The company reported full-year 2024 revenue of $2.109 billion, representing 11.8% growth
.

8. Fortrea

In November 2024, Fortrea launched new enhancements to Global Trial Connect, the company's suite of digital, data and operational solutions for clinical trials
.

9. Worldwide Clinical Trials

For the second year in a row, data from the Industry Standard Research (ISR) report showed that Worldwide Clinical Trials was the highest-rated Phase II/III CRO across several categories
.
Worldwide's therapeutic expertise consists of five key areas: cardiovascular and metabolic diseases, oncology, neuroscience, rare disease, cell and gene therapy, and immune-mediated inflammatory diseases
.

Key Market Trends for 2025

Three forces are changing the rules: artificial intelligence is slicing weeks off data tasks, decentralised trials let volunteers join from home rather than hospital wards, and study sites are shifting towards Asia, Latin America, and Eastern Europe
.

The global CRO market was estimated to be worth up to $82 billion in 2024, and is expected to reach USD 139.42 billion by 2029
.

When selecting a CRO, consider factors like therapeutic expertise, global reach, technological capabilities, and track record in your specific indication.
In 2025, winners will be those CROs that blend scale with agility and keep patients at the heart of every trial
.

Selecting the "best" CRO depends on the specific needs of your clinical trial, including therapeutic area, phase of development, geographic requirements, and budget. However, some consistently highly-regarded CROs include:

Top CROs in terms of revenue and market presence:

• Thermo Fisher Scientific (PPD Division): A leading company with a revenue of $6 billion in Q2 2025. Thermo Fisher acquired PPD, making it one of the largest global clinical trial service organizations.
• IQVIA: With $4.02 billion in revenue in Q2 2025, IQVIA has the largest revenue base in the CRO market and an unrivaled analytics stack. They operate in over 100 countries. IQVIA provides end-to-end solutions, from early-phase development to commercialization.
• ICON plc: ICON reported $2.02 billion in Q2 2025. ICON was the most used CRO for new study starts in 2024. They offer a full range of consulting, clinical development, and commercialization services.
• WuXi AppTec: Based in China, with $2.87 billion in revenue, WuXi AppTec is central to Asia's expanding biotech economy.
• Charles River Laboratories: Maintaining dominance with strong preclinical services and operating in over 20 countries.

Other leading CROs:

• Medpace: Delivers standout growth with $603 million in revenue and a 14.2% year-over-year increase. Medpace prides itself on close relationships with partners.
• Parexel: Parexel is known for expertise in oncology and rare disease trials. They operate in more than 50 countries and emphasize a patient-centric approach.
• Syneos Health: A fully integrated biopharmaceutical solutions organization with 29,000+ employees working across more than 110 countries.
• Fortrea: A subsidiary of Labcorp, Fortrea provides comprehensive drug and medical device development services across Phase I-IV clinical trials.
• PSI: A privately owned CRO with a strong focus on oncology and hematology trials. PSI completes a high percentage of studies on time.
• TFS HealthScience: A mid-size CRO that partners with biotechnology and pharmaceutical companies.
• Worldwide Clinical Trials: A full-service global CRO that creates customized strategies to support biotech and biopharma companies in clinical drug development.

Smaller or more specialized CROs:

• Lindus Health: Specializes in decentralized clinical trials (DCTs).
• Ergomed: Blends full-service CRO offerings with specialist pharmacovigilance expertise.
• Keyrus Biopharma: Specializes in data management, biostatistics, medical writing, and regulatory affairs.
• CTI: A full-service CRO that operates in more than 60 countries across the world.

When choosing a CRO, consider factors such as their experience in your therapeutic area, their geographic reach, their technological capabilities, and their overall reputation.

The top Contract Research Organizations (CROs) for clinical trials in 2025-2026, based on recent industry analyses, include IQVIA, ICON, Parexel, Syneos Health, Fortrea, Medpace, and Lindus Health. These rankings vary by source due to differing criteria like revenue, innovation, therapeutic expertise, and recent milestones, with no universal consensus.

Most Frequently Ranked CROs

The following CROs appear across multiple sources as leaders, often praised for global reach, technology integration, and trial efficiency:

• IQVIA: Excels in AI-driven insights, data analytics, and patient-centric solutions; ranked top in multiple lists with vast data assets for predictive modeling.
• ICON plc: Leads in large-scale trials, adaptive designs, and 2024 acquisitions enhancing digital and government-funded research; most used for new study starts in 2024.
• Parexel: Strong in oncology, rare diseases, real-world evidence, and decentralized trials; backed by private equity for AI-enhanced planning.
• Syneos Health: Offers full clinical development, bioanalytical services, and decentralized solutions; third-largest by revenue (USD 5.39B in 2023).
• Fortrea: Focuses on Phase I-IV trials with digital enhancements like Global Trial Connect; spun off from Labcorp for efficiency.

Other Notable CROs

Emerging or specialized leaders highlighted for innovation and milestones:

• Medpace: Stands out for strategic positioning and oncology/rare disease expertise.
• Lindus Health: Innovates in decentralized trials via FUSED platform for speed and engagement.
• PPD (Thermo Fisher): Leverages lab networks for end-to-end services and real-world evidence.
• Worldwide Clinical Trials: Recognized for DEI awards, rare disease partnerships, and 30+ years of expertise.
• Ergomed, PSI, Quanticate: Noted for pharmacovigilance, oncology reliability (93% on-time completion), and data-focused services.

Rankings depend on factors like trial phase, therapeutic area, and geography; sponsors should evaluate based on specific needs such as decentralized trials (e.g., Lindus) or large-scale execution (e.g., ICON). Sources reflect 2024-2025 data, with potential shifts by 2026.